Share
David Arkowitz
iBio, Inc., an AI-driven innovator in precision antibody immunotherapies, has appointed biotech industry veterans David Arkowitz and António Parada to its Board of Directors, strengthening its expertise in finance, leadership, and antibody discovery.
David Arkowitz, currently Chief Financial Officer at Alkeus Pharmaceuticals, brings extensive financial and operational experience. His background includes CFO and business development leadership roles at Seres Therapeutics, Flexion Therapeutics, and Visterra, Inc., where he managed finance, corporate planning, and strategic growth. He also serves on the board of Kineta and has held board and audit committee chair roles at multiple biotech companies.
António Parada, an expert in antibody drug discovery, is the Founder and CEO of FairJourney Biologics, a leading antibody discovery CRO. His experience includes leadership roles at Instituto de Biologia Molecular e Celular (IBMC), IPO Porto – Cancer Hospital, and Ablynx’s Centre of Excellence in Phage Display, a Sanofi subsidiary.
These strategic appointments position iBio for continued growth and innovation in AI-powered antibody discovery.
